Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ganguly, Siddhartha  [Clear All Filters]
2023
Murthy GSubramania, Kim S, Estrada-Merly N, Abid MBilal, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023.
Vose JM, Ganguly S, Bierman PJ, R Bociek G, Lunning M, Lyden L, Meza JL, Caimi PF, Armitage JO. Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study. Br J Haematol. 2023.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
2022
Murthy HS, Ahn KWoo, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022.
2021
Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, Agrawal V, A Al-Homsi S, Assal A, Bacher U, et al. Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. Transplant Cell Ther. 2021.
Bhatt VRaj, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MMAl, Badawy SM, Beitinjaneh A, Ganguly S, et al. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. Transplant Cell Ther. 2021.
Oran B, Ahn KWoo, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, et al. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Mushtaq MUmair, Shahzad M, Chaudhary SGull, Luder M, Ahmed N, Abdelhakim H, Bansal R, Balusu R, DeJarnette S, Divine C, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients. Transplant Cell Ther. 2021.
Singh A, Dandoy CE, Chen M, Kim S, Mulroney CM, Kharfan-Dabaja MA, Ganguly S, Maziarz RT, Kanakry CG, Kanakry JA, et al. Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients. Transplant Cell Ther. 2021.
2020
Britt A, Mohyuddin GRehman, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, et al. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res. 2020;95:106402.
Ganguly S, Cortes JE, Krämer A, Levis MJ, Martinelli G, Perl AE, Russell NH, Arunachalam M, Santos CDos, Gammon G, et al. Clinical Outcomes in Patients With FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplant After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Biol Blood Marrow Transplant. 2020.
Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, et al. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.
Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, et al. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020;4(6):983-992.
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Solomon SR, St Martin A, Zhang M-J, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LAnn, Brunstein C, Chhabra S, Perez MAngel Diaz, et al. Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. Biol Blood Marrow Transplant. 2020.
Soder RP, Dawn B, Weiss ML, Dunavin N, Weir S, Mitchell J, Li M, Shune L, Singh AK, Ganguly S, et al. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. Stem Cell Rev Rep. 2020.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
Gowin K, Ballen K, Ahn KWoo, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
2019
Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Díaz MÁngel, Chhabra S, Cerny J, Copelan E, et al. Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019.
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJan, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, Anderlini PN, Beitinjaneh AM, Bredeson C, Cerny J, et al. The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time. Biol Blood Marrow Transplant. 2019.
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, et al. Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2019.
Naik S, Riches M, Hari P, Soyoung K, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, et al. Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. Transpl Infect Dis. 2019:e13145.
2018
Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Prohaska L, Mahmoudjafari Z, Shune L, Singh A, Lin T, Abhyankar S, Ganguly S, Grauer D, McGuirk J, Clough L. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther. 2018.

Pages